Arcellx

Arcellx Cash Conversion Cycle

Delisted

The Cash Conversion Cycle (CCC) of Arcellx (ACLX) as of Nov 21, 2026 is -304.77. In the previous year, Cash Conversion Cycle (CCC) was -138.94 — a change of 119.35% (lower).

Cash Conversion Cycle

-304.77

YoY

119.35%

Last updated:

Cash Conversion Cycle (CCC) of Arcellx is 2025 -304.77 . Cash Conversion Cycle (CCC) of Arcellx was 2024 -138.94 . It decreases by 119.35% lower compared to the previous year.

The Arcellx Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2019
-1,954.88 USD
Jan 1, 2020
-292.46 USD
Jan 1, 2021
-467.38 USD
Jan 1, 2022
-1,485.77 USD
Jan 1, 2023
-468.60 USD
Jan 1, 2024
-138.94 USD
Jan 1, 2025
-304.77 USD
The Arcellx Cash Conversion Cycle history
YEARCash Conversion CycleYoY
-304.77+119.35%
-138.94-70.35%
-468.60-68.46%
-1,485.77+217.89%
-467.38+59.81%
-292.46-85.04%
-1,954.88—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Arcellx Stock analysis

What does Arcellx do? Arcellx, Inc develops innovative immunotherapies for cancer and incurable diseases, focusing on controllable cell therapies. The company's lead product CART-ddBCMA, a BCMA-targeting ddCAR therapy, is in a pivotal Phase II trial for relapsed or refractory multiple myeloma. Arcellx also advances two clinical-stage ARC-SparX programs: ACLX-001 for BCMA-targeting in multiple myeloma and ACLX-002 for CD123-targeting in acute myeloid leukemia and myelodysplastic syndrome. These therapies are developed using the company's D-Domain technology, with the goal of providing treatment options for patients with limited alternatives. Arcellx generates revenue through the development and clinical advancement of its cell therapy programs. The company's primary focus is on securing funding from strategic partnerships and clinical trial sponsorships to support its research and development activities. The key segments include patients with relapsed or refractory multiple myeloma, acute myeloid leukemia, and high-risk myelodysplastic syndrome, who are the target populations for its therapies. The company's lead program, CART-ddBCMA, is being evaluated in a pivotal Phase II trial, which is critical for advancing the therapy toward potential market approval. The firm's development pipeline includes CART-ddBCMA, ACLX-001, and ACLX-002, all leveraging the D-Domain technology for controllable cell therapies. Arcellx's business model centers on advancing these therapies through clinical trials to demonstrate efficacy and safety, with the ultimate goal of commercializing them for patients with unmet medical needs. The company's strategic partnerships and clinical trial sponsorships are essential for funding the progression of its programs from preclinical to clinical stages. Arcellx is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Arcellx stock

Cash Conversion Cycle (CCC) of Arcellx is -304.77 in 2025.

Cash Conversion Cycle (CCC) of Arcellx changed from -138.94 to -304.77, representing a 119.35% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) Arcellx since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s Arcellx with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Arcellx

All Key Metrics — Arcellx